Rua Life Sci. Regulatory News (RUA)

25 June 2020

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Animal Pilot Study

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), is pleased to announce the first surgical implant of an Elast-EonTM sealed vascular graft as part of its prototype evaluation prior to design freeze.

The implant procedure went well with the graft performance meeting the primary targets of suture line performance and blood sealing. Following initial findings, alterations to the selvedge line have now been incorporated into grafts for phase 2 of the study with the ongoing intention of examining the healing of the graft compared to a control as a secondary target. It is intended to commence phase 2 as soon as possible and further updates will be provided after examination of the explanted grafts.

Bill Brown, Chairman of RUA Life Sciences, commented: "First animal implant is always a major milestone in the development of new medical devices and we are delighted to have successfully sealed a textile graft with Elast-Eon™. This brings us another step closer to reaching design freeze and moving forward to regulatory testing."

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0) 77 3071 8296

David Richmond, CEO Tel: +44 (0) 78 9999 6400

Shore Capital

Tom Griffiths/David Coaten Tel: +44 (0)20 7408 4080

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are: